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Abstract
Objective
High sensitivity plasma cardiac troponin-I (cTnI) is emerging as a strong predictor of cardiac
events in a variety of settings. We have explored its utility in patients with myotonic dystro-
phy type 1 (DM1).
Methods
117 patients with DM1 were recruited from routine outpatient clinics across three health
boards. A single measurement of cTnI was made using the ARCHITECT STAT Troponin I
assay. Demographic, ECG, echocardiographic and other clinical data were obtained from
electronic medical records. Follow up was for a mean of 23 months.
Results
Fifty five females and 62 males (mean age 47.7 years) were included. Complete data were
available for ECG in 107, echocardiography in 53. Muscle Impairment Rating Scale score
was recorded for all patients. A highly significant excess (p = 0.0007) of DM1 patients pre-
sented with cTnI levels greater than the 99th centile of the range usually observed in the gen-
eral population (9 patients; 7.6%). Three patients with elevated troponin were found to have
left ventricular systolic dysfunction (LVSD), compared with four of those with normal range
cTnI (33.3% versus 3.7%; p = 0.001). Sixty two patients had a cTnI level < 5ng/L, of whom
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only one had documented evidence of LVSD. Elevated cTnI was not predictive of severe
conduction abnormalities on ECG, or presence of a cardiac device, nor did cTnI level corre-
late with muscle strength expressed by Muscle Impairment Rating Scale score.
Conclusions
Plasma cTnI is highly elevated in some ambulatory patients with DM1 and shows promise
as a tool to aid cardiac risk stratification, possibly by detecting myocardial involvement. Fur-
ther studies with larger patient numbers are warranted to assess its utility in this setting.
Introduction
Myotonic dystrophy type 1 (DM1) is a dominantly inherited, multisystem condition affecting
approximately 1 in 8,000 of the population.[1] It is caused by expansion of a CTG trinucleotide
repeat in the 30-untranslated region of the DMPK gene. The trinucleotide repeat is genetically
unstable in the germline, with offspring frequently inheriting a larger repeat expansion than
the transmitting parent.[2] This gives rise to the phenomenon of genetic anticipation, with ear-
lier onset and more severe symptoms often seen in successive generations of an affected family.
Cardiac manifestations of DM1 include cardiomyopathy, conducting system disease and
arrhythmias.[3, 4] Non-cardiac features include frontal balding, ptosis, skeletal muscle weak-
ness, delayed muscle relaxation, diabetes and cognitive deficits.[5] Premature mortality is most
commonly due to cardiac arrhythmias and respiratory failure.[6, 7] Abnormalities of the sur-
face electrocardiogram are common, and include prolongation of the PR interval, axis-devia-
tion and broadening of the QRS complex.[8] Arrhythmias may also occur including atrial
fibrillation and flutter, ventricular tachycardia and varying degrees of atrioventricular block.
In several case series, advanced cardiac involvement of the conducting system was linked to
sudden death and cardiovascular events.[9–11] Overt cardiomyopathy is relatively rare,
although cardiac MR studies suggest that more subtle changes in myocardial trabeculation and
mass are more common than previously recognized.[8, 12, 13]
Cardiology follow up of patients with DM1 is often requested by clinical neurology or
genetics teams before the appearance of clear cardiac involvement. The 12 lead ECG is com-
monly used as a screening tool, sometimes in association with 24 hour ambulatory monitoring
and echocardiography[14] to identify those at higher risk of future cardiac events, or those
who may benefit from treatment, such as patients with severe asymptomatic LVSD. Even in
the absence of symptomatic dysrhythmia, insertion of a permanent cardiac pacemaker or
implantable cardioverter defibrillator may be indicated in patients with high grade atrioven-
tricular block or ventricular arrhythmias.[4] There is some evidence that the presence of left
ventricular systolic impairment is associated with a worse prognosis.[10]
Plasma cardiac troponin has emerged as a useful clinical tool to identify patients at
increased risk of cardiac events in a range of clinical settings.[15–18] We hypothesised that
plasma cardiac troponin I (cTnI) levels may be elevated and act as a biomarker of cardiac
involvement in DM1, and thus could prove a useful tool for risk stratification in this group.
Methods
Ethical considerations
The study, including consenting procedure, was reviewed by the West of Scotland Research
Ethics Committee (reference 08/S0703/121). Multi-centre ethical approval was granted, and
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adherence to PLOS ONE policies on sharing data
and materials.
patients were recruited from three health authority regions in Scotland (NHS Greater Glasgow
and Clyde, NHS Lothian, and NHS Grampian). All participants gave written, informed
consent.
Patient recruitment
Patients were identified during routine follow-up appointments at cardiology, clinical genetics
and neurology outpatient clinics by their usual care team. Eligibility was defined as any patient
with a genetically confirmed diagnosis of myotonic dystrophy type 1. Patients with a recent
hospital admission with chest pain or a suspected cardiac event, as well as those currently
experiencing angina or cardiac-type chest pains were excluded. Patients were not excluded on
the basis of additional comorbidities such as diabetes or hypertension. No patients were
known to have significant renal impairment. Demographic, clinical, electrocardiogram (ECG),
echocardiogram (echo) data collected as part of routine clinical follow-up were obtained from
electronic medical records. Muscle Impairment Rating Scale (MIRS) scores, routinely docu-
mented during annual review appointments, were also collected. The MIRS is an ordinal five-
point rating scale of muscle impairment, validated specifically in DM1 (1 = no impairment;
2 = minimal signs; 3 = distal weakness; 4 = mild to moderate proximal weakness; 5 = severe
proximal weakness). [19]
Blood sampling and troponin assay
Whole blood was sent directly to the clinical biochemistry department for troponin analysis,
or samples were centrifuged at 1000 x g for 15 minutes and stored at -40˚C before being trans-
ported frozen for analysis. Cardiac TnI was measured using a high sensitivity assay (ARCHI-
TECT STAT Troponin I assay; Abbott Laboratories). This assay has a limit of detection of
1.2 ng/L, with a coefficient of variation of 23% at the limit of detection (1.2 ng/L) and less than
10% at 6 ng/L. [20] The upper reference limit, determined by the manufacturer as the 99th cen-
tile of samples from 4590 presumed healthy individuals, is 34 ng/L in men and 16 ng/L in
women.[21] This is consistent with studies in other healthy populations.[22, 23]
Genetic analysis
CTG repeat expansion sizes were estimated by small pool PCR as previously described.[24]
Four reactions, each using 300 pg blood genomic DNA template, were performed for each
patient. CTG repeat lengths were estimated by comparison against DNA fragments of known
length in the molecular weight marker. The lower boundary of the expanded molecules in
small pool PCRs using blood DNA was used to estimate the inherited, or “progenitor”, repeat
length, [24] which is the major determinant of age at onset of symptoms.[25]
Echocardiography studies were performed in centres accredited by the British Society of
Echocardiography, and conducted according to national protocols.[26]
Statistics
Linear regression analyses were undertaken using SPSS for Macintosh software (Version 22.0.
Armonk, NY; IBM Corp.). Two-tailed Fisher’s exact test was performed using GraphPad
QuickCalcs website (La Jolla, California, USA. http://graphpad.com/quickcalcs/contingency1.
cfm; accessed May 2016).
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Results
Patient cohort
One hundred and seventeen patients with a diagnosis of DM1 were recruited and had cTnI
level measured. These included 55 females and 62 males, with a mean age of 47.7 years (range
of 21 to 72). Demographic and clinical data relating to diagnosis, presence of implanted car-
diac device, associated comorbidity and MIRS score contemporaneous to cTnI sampling were
available for the entire cohort. Complete ECG data were available for 107 patients, with partial
information (eg. clinic letter description) for a further three. Echo data were available for 53
patients. Patients were followed up for a mean of 23 months (range 7 to 32 months) after cTnI
testing.
Cardiac devices (including permanent pacemaker, internal cardioverter defibrillator or car-
diac resynchronisation therapy) had been previously implanted in 21 patients. Echo had been
carried out as part of normal clinical care within the previous 36 months and/or during the fol-
low-up period in 53 patients. ECG data were available within 12 months for 107 individuals.
Genetic data (estimated progenitor allele length and modal allele lengths) were available for
111 individuals.
Outcomes
Seven patients died during the follow-up period. Three were sudden deaths, two of which were
attributed to ischaemic heart disease (Table 1).
Table 1. Details of patient deaths during study period.
Study number
(sex)
Age at
death
cTnI
(ng/L)
Comorbidities Sudden death of
suspected cardiac
cause?
Details
DMGV1 (F) 67 18 Permanent pacemaker, concentric left
ventricular hypertrophy
No Aspiration event during evening meal.
DMGV105 (M) 47 2 Diabetes mellitus type 2 Yes Unable to obtain detailed information. Recent
admission with type II respiratory failure. Death
certificate gives cause of death as hypoxic brain
injury due to out-of-hospital cardiac arrest.
DMGV117 (F) 66 28 Dilated cardiomyopathy, mitral
regurgitation, coronary artery disease,
atrial fibrillation, dyslipidaemia
Yes Witnessed sudden collapse. Ambulance crew
confirmed VF arrest. ECG during attempted
resuscitation in hospital consistent with extensive
myocardial infarction.
DMGV129 (M) 71 5 Polycythaemia, right frontal lobe
cerebral infarction, previous
anteroseptal myocardial infarction.
Yes Sudden death. Post-mortem examination concluded
cause to be coronary artery disease.
DMGV141 (F) 58 9 Endometrial adenocarcinoma, poor
mobility
No Admitted to hospital with ankle fracture. Gradual
deterioration over several days with type II
respiratory failure, paroxysmal atrial fibrillation and
confusion. Developed in-hospital cardiac arrest with
complete heart block. Attempts at resuscitation were
unsuccessful.
DMGV187 (M) 70 7 Cerebrovascular disease, permanent
pacemaker, falls, poor cough.
No Multiple admissions with deterioration in mobility and
confusion, attributed to aspiration pneumonia.
Insertion of a percutaneous gastrostomy was
discussed, which the patient declined. Subsequently
died at home with palliative care involvement.
DMGV227 (M) 68 8 Used non-invasive ventilation overnight No Aspiration pneumonia
https://doi.org/10.1371/journal.pone.0174166.t001
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Age and muscle power at sampling
Previous authors have observed a positive correlation between age and increasing cTnI level in
a population-based cohort.[27] We therefore used linear regression analysis to investigate the
relationship between age and cTnI in our DM1 cohort, revealing a positive correlation overall
(p = 0.037). This correlation was greater in female patients only (p = 0.022), but was not signifi-
cant among male patients alone (p = 0.726).
Troponin level did not correlate with muscle power as measured by MIRS score in the pop-
ulation as a whole (p = 0.952), nor in male or female-specific sub-analyses (p = 0.801 and
p = 0.783 respectively).
Elevated troponin
Using sex-specific thresholds to define the upper limit of the expected cTnI range (34ng/L in
males, 16ng/L in females), nine patients in our cohort (three males, six females) had elevated
cTnI (Table 2). This confirms that substantial cTnI elevations occur significantly more fre-
quently in DM1 patients compared with the manufacturertlycontrol population (p = 0.0007 in
two-tailed Fisheril exact test).[21] Echo data were available for five patients with elevated cTnI,
of whom three showed LV impairment (one mild, one moderate, one severe), and one mild
LV hypertrophy. As shown in Table 2, the documented prevalence of LVSD was substantially
higher in patients with elevated cTnI compared to those with normal cTnI, although rates of
device implantation were similar. There was a trend toward increased mortality in the high
cTnI group that did not reach statistical significance. Among the nine patients with
cTnI > 99th centile, four had a MIRS score of 4/5, four 3/5 and one 2/5.
Low troponin
A recent prospective cohort study demonstrated a strong negative predictive value of troponin
level< 5 ng/L in patients presenting with suspected acute coronary syndrome.[20] In our
cohort, 62/117 patients had troponin < 5 ng/L (Table 3). Echo data were available for 26, of
whom only one had LV dysfunction, which was considered borderline low with an ejection
fraction of 49%. A further one patient had mild LV hypertrophy. The difference in prevalence
of LVSD compared to all others in the cohort approached statistical significance (p = 0.0502).
The average MIRS score of patients with cTnI < 5 ng/L was 3.41/5 (range 1 to 5), compared
with 3.38/5 (range 2 to 5) among those with cTnI TnI nge. Three patients with troponin in the
Table 2. Prevalence of left ventricular dysfunction, device implantation and death during follow-up in DM1 patients with cTnI above population
99th centile compared to those with troponin in the population normal range.
cTnI > general population 99th centile (n. 9) cTnI in population normal range (n. 108) p
Proven LV dysfunction 3 (33.3%) 4 (3.7%) 0.010
Pacemaker or ICD 2 (22.2%) 19 (17.6%) 0.663
Death during follow-up 2 (22.2%) 5 (4.6%) 0.091
https://doi.org/10.1371/journal.pone.0174166.t002
Table 3. Prevalence of left ventricular dysfunction, device implantation and death during follow-up in
DM1 patients with cTnI < 5 ng/L compared to those with cTnI5ng/L.
cTnI < 5 ng/L (n. 62) cTnI 5 ng/L (n. 55) p
Proven LV dysfunction 1 (1.6%) 6 (10.9%) 0.050
Pacemaker or ICD 12 (19.4%) 9 (16.4%) 0.810
Death during follow-up 1 (1.6%) 6 (10.9%) 0.050
https://doi.org/10.1371/journal.pone.0174166.t003
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normal range but lence of LVSD compared to all oECG data were available for two of these,
both males, who had normal PR and QRS values, and QTc of 410 ms and 438 ms respectively.
Only one patient with cTnI < 5ng/L died during the follow-up period. The limited data
available suggest the cause of death was an out-of-hospital cardiac arrest, although the patient
had a recent hospital admission with type II respiratory failure.
Conducting system disease and Groh criteria
Among DM1 patients, the presence of PR interval > 240 ms, QRS> 120 ms, atrial tachyar-
rhythmias and/or any rhythm other than sinus (Groh criteria) have previously been shown to
predict sudden death.[4, 9]
Thirty one patients in our cohort met Groh ECG criteria, including five with PR> 240ms
and 18 with QRS> 120 ms. Ten patients were not in sinus rhythm; three in atrial fibrillation,
three in atrial flutter and four with a pacemaker-dependent rhythm. Neither elevated cTnI nor
cTnI < 5 ng/L predicted the presence of high risk ECG changes (Table 4). There was a trend
towards increased mortality among patient with any high risk ECG features that did not reach
statistical significance, and non-sinus rhythm ECG was present in all three patients meeting
Groh criteria who died during follow-up (p = 0.013).
ECG data were available for four of the five patients with LVSD who did not meet Groh cri-
teria. PR duration was normal in two, borderline in two (198 ms and 204 ms respectively), and
QTc 438 ms in all. Four of these five patients had cTnI 5 ng/L, including one above the
population 99th centile.
Linear regression analysis showed no significant correlation between cTnI measurement
and either PR interval or QRS duration for the cohort as a whole. Likewise correlations
between PR interval and QRS duration themselves were not significant. Sub-analysis in male
patients only, however, revealed a significant positive correlation between PR interval and
cTnI level (p = 0.025) and a strong correlation between QRS duration and PR interval
(p = 0.002). These were non-significant in female patients (p = 0.682 and p = 0.992
respectively).
Genetic data
The cohort was highly genetically heterogeneous, both in terms of modal CTG repeat length
(range 46 to 1264 repeats, mean 442 repeats) and estimated progenitor allele length (range 43
to 730 repeats, mean 222 repeats).
No correlation was observed between cTnI level and progenitor allele length nor modal
allele length in univariate analysis of the cohort as a whole. This was also true in multivariate
analysis integrating both age at sampling and allele size. In sex-specific sub-analysis, only the
correlation between cTnI and modal allele length in female patients approached statistical sig-
nificance (p = 0.079).
Table 4. Clinical features, cTnI levels and outcome in patients with high risk ECG features compared to those without.
High risk ECG features present (n. 31) No high risk ECG features recorded (n. 86) p
Proven LV dysfunction 2 (6.5%) 5 (5.8%) 1.000
Pacemaker or ICD 13 (41.9%) 8 (9.3%) < 0.001
Death during follow-up 3 (9.7%) 4 (4.7%) 0.380
cTnI > population 99th centile 3 (9.7%) 6 (7.0%) 0.698
cTnI < 5 ng/L 14 (45.2%) 48 (55.8%) 0.402
https://doi.org/10.1371/journal.pone.0174166.t004
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Discussion
In clinical practice, the role of plasma cardiac troponin measurement as a screen for myocar-
dial necrosis in the context of acute chest pain is well established. However, high-sensitivity
cardiac troponin assays have also shown promise as prognostic biomarkers of cardiovascular
risk in a variety of ambulatory outpatient settings, including among those with known vascular
disease,[28, 29] the elderly [30, 31] and in general population-based studies.[27, 32–35] The
cause of chronic, low-level troponin elevation in these populations is uncertain, although spec-
ulated mechanisms include subclinical ischaemia, microvascular dysfunction or apoptosis of
myocytes.[36]
In this context, we present exploratory data relating to cTnI from 117 patients with DM1,
recruited from those attending routine review appointments. Remarkably, we found that 9
(7.6%) have a cTnI above the general population 99th centile. This strongly suggests that cTnI
levels act as a marker of a component of the DM1 disease process, although the precise clinical
significance of elevated cTnI and the pathological processes that it represents in this group are
unclear.
Elevated levels of the T subunit of cardiac troponin (cTnT) have previously been reported
in patients with a range of myopathic conditions. The origin of elevated cTnT in these cases is
not fully resolved, although broadly they were not accompanied by an increase in cTnI except
in some patients with concomitant cardiomyopathy [37–42]. There is some direct evidence
that cTnT may be produced by regenerating skeletal muscle.[43] Very recently, Valaperta et al
explored a range of cardiac biomarkers in a mixed cohort of 59 patients with DM1 or myo-
tonic dystrophy type 2, comparing to both unaffected controls and controls with comparable
cardiac morbidity. They found significantly higher levels of both serum cTnT and cTnI in
those with myotonic dystrophy compared with controls, and a weakly significant association
of both measures with disease duration. Skeletal muscle biopsy revealed expression of cTnT at
the mRNA level in both healthy and DM1 muscle, and expression at protein level was detected
by M7 detector antibody, though negative with 5D8 capture antibody. No measures of cTnI in
this cohort were above the given cut-off value (26 ng/L; the non-sex adjusted population 99th
centile), and there were only two patients with manifest left ventricular impairment, limiting
analysis with respect to heart muscle disease [44].
To our knowledge, there is no evidence that cTnI is expressed in healthy or diseased skeletal
muscle.[45, 46] In the cohort we present, the association observed between cTnI level and
presence of LV impairment, significant correlation with PR interval in male-specific subanaly-
sis and the absence of correlations with muscle impairment as measured by MIRS score all
strongly support a cardiac origin of the cTnI detected.
The 12-lead ECG currently serves as the cornerstone of cardiac assessment in DM1, with
Groh criteria (PR> 240 ms, QRS> 120 ms, rhythm other than sinus, second-degree or third-
degree AV block) shown to be predictive of sudden death and cardiac morbidity.[4, 9] Our data
suggest that an elevated cTnI does not reliably distinguish patients with severe conduction
abnormalities; 31 patients had high-risk ECG changes, among whom only three had elevated
cTnI. Conversely however, we identified at least four patients with significant LVSD who would
not be identified by Groh criteria on surface ECG alone, of whom three had cTnI 5 ng/L.
Our findings therefore suggest that cTnI level represents a component of the cardiac phenotype
distinct from progressive conducting system disease, apparently mapping more closely with
myocardial involvement. This supports a potential role for combined ECG and biomarker mea-
surement in cardiac screening for patients with DM1.
Patients with DM1 also have a high prevalence of risk factors for premature vascular dis-
ease, including insulin resistance,[47] obesity, and sedentary lifestyle.[48, 49] Despite this, risk
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from cardiovascular disease in DM1 is a relatively neglected area of investigation, with the vast
majority of literature focused on DM1-specific risk of arrhythmia. We observed two deaths
attributed to ischaemic heart disease in our cohort, one of whom had been found to have an
elevated cTnI. This highlights coronary heart disease as a possible additional important cause
of death in DM1 patients, and suggests value in further investigation of high-sensitivity tropo-
nin assay not only as a marker of DM1-specific heart disease, but also of more general cardio-
vascular risk in this group of patients.
We did not observe any correlation between cTnI level and CTG repeat length, expressed
either as modal allele length or estimated progenitor allele length. This remained true in multi-
variate analyses to account for the patient’s age at troponin sampling. This is despite the small-
pool PCR techniques used to measure the CTG repeat in this study having been shown to be
superior in detecting genotype-phenotype correlations compared with traditional methods.
[25] The absence of direct correlation between cTnI and genotype would however support
cTnI as a marker of a multifactorial process, rather than a primary effect of the CTG repeat
expansion on cardiac myocyte metabolism. Of note, elevated cTnI was not seen in any patients
with an estimated progenitor allele length greater than 363 repeats. Larger CTG expansions
are associated with shorter life expectancy in DM1,[50] and those with the severe, congenital
onset form are much more likely to die from respiratory complications than cardiac arrhyth-
mia, cardiomyopathy or sudden unexplained death.[51] The absence of high cTnI levels in
those with very large repeat expansions therefore may simply reflect a lower burden of progres-
sive cardiac disease due to reduced long-term survival.
Strengths of this study include sampling of cTnI from a large cohort of individuals with
DM1, recruited from routine outpatient clinics across three different health regions, includ-
ing annual review appointments offered to all individuals with DM1 known to their regional
Clinical Genetics service. There is therefore little sampling bias in terms of severity of cardiac
phenotype. The study is however significantly limited by a lack of a formal prospective clini-
cal and cardiac review linked to the blood sampling, with all ECG and echocardiogram data
obtained from electronic records. Patients therefore only underwent investigations that
were requested as part of routine clinical care, and in many cases these were not closely
contemporaneous to blood sampling. As a result, clinical data were incomplete, with echo-
cardiogram results in particular only available for 44%. The correlations we describe with
LVSD therefore assume absence of heart muscle involvement in patients for whom echo
data was not available. Furthermore, analysis of correlations with PR interval inevitably
excludes the 10 patients described with atrial fibrillation, atrial flutter or pacemaker-
dependent ECGs. Absence of ECG data for seven patients, including one with elevated cTnI
and one who died during follow-up (DMGV227), means that some patients with potentially
severe phenotypes were excluded from these analyses. Finally, although finding nine individ-
uals with cTnI above the population 99th centile is itself remarkable, this is a relatively small
number in absolute terms for further analysis. We therefore present these results as explor-
atory data, suggesting value in further systematic analysis of cTnI and other cardiac biomark-
ers in DM1.
Conclusions
In ambulatory patients with DM1, plasma cTnI level appears to map with the presence of
LVSD but does not correlate with advanced conducting system disease on surface ECG. These
findings suggest that high sensitivity cTnI holds promise as a tool to aid risk stratification of
patients with myotonic dystrophy, possibly adding additional value to surface ECG in identify-
ing those at increased risk of cardiovascular disease or those with manifest cardiac muscle
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involvement. Further studies of cardiac biomarkers in DM1 involving larger patient numbers
and longer-term formal follow-up are therefore warranted.
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